C. R. Bard
Clinical trials sponsored by C. R. Bard, explained in plain language.
Medical device company, acquired by BD, known for vascular and urology products.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Could a less invasive catheter replace the tube in intensive care? Results expected Oct 2026 (estimated)
- New balloon could help dialysis patients avoid repeat procedures Results expected Apr 2027 (estimated)
- New device aims to simplify dialysis access for kidney patients Results expected Jun 2027 (estimated)
-
New patch may stop dangerous air leaks after lung surgery
Prevention Not yet recruitingThis study tests a special patch (TissuePatch SF) used during lung surgery to prevent air leaks. About 250 adults having planned lung surgery will receive the patch, and doctors will check how well it seals the lung and if it causes any side effects. The goal is to see if the pat…
Sponsor: C. R. Bard • Aim: Prevention
Last updated Jun 27, 2026 09:04 UTC
-
Could a less invasive catheter replace the tube in intensive care?
Knowledge-focused Not yet recruitingThis pilot study is testing whether an external catheter called PureWick can measure urine output in adult ICU patients as accurately as the standard indwelling catheter (Foley tube). The study will compare how much urine each method captures and will ask ICU clinicians whether t…
Sponsor: C. R. Bard • Aim: Knowledge-focused
Last updated Aug 06, 2026 00:00 UTC